Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Merck
Cipla
Fuji
Healthtrust
Express Scripts
Novartis
McKinsey
Chubb
UBS

Generated: August 17, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,486,972 protect, and when does it expire?


Patent ► Subscribe protects SUBSYS and is included in one NDA. There has been one Paragraph IV challenge on Subsys.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: ► Subscribe

Title:Sublingual fentanyl spray
Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
Inventor(s): Kottayil; S. George (Long Grove, IL), Goskonda; Venkat R. (Gurnee, IL), Zhu; Zhongyuan (Vernon Hills, IL), Parikh; Neha (Chicago, IL), Kattookaran; Linet (Mount Prospect, IL)
Assignee: Insys Therapeutics, Inc. (Phoenix, AZ)
Application Number:11/698,739
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Insys Dev Co Inc
SUBSYS
fentanyl
SPRAY;SUBLINGUAL202788-001Jan 4, 2012RXYesNo► Subscribe► SubscribeY
Insys Dev Co Inc
SUBSYS
fentanyl
SPRAY;SUBLINGUAL202788-002Jan 4, 2012RXYesNo► Subscribe► SubscribeY
Insys Dev Co Inc
SUBSYS
fentanyl
SPRAY;SUBLINGUAL202788-003Jan 4, 2012RXYesYes► Subscribe► SubscribeY
Insys Dev Co Inc
SUBSYS
fentanyl
SPRAY;SUBLINGUAL202788-004Jan 4, 2012RXYesNo► Subscribe► SubscribeY
Insys Dev Co Inc
SUBSYS
fentanyl
SPRAY;SUBLINGUAL202788-005Jan 4, 2012RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,460Sublingual fentanyl spray and methods of treating pain► Subscribe
9,642,797Sublingual fentanyl spray and methods of use to treat pain► Subscribe
9,289,387Method of treating pain by administering sublingual fentanyl spray► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1976521► Subscribe
Russian Federation2432950► Subscribe
Russian Federation2008130763► Subscribe
Portugal1976521► Subscribe
New Zealand569949► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
McKinsey
Federal Trade Commission
Julphar
US Department of Justice
Deloitte
Healthtrust
Fuji
Boehringer Ingelheim
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot